Replies to post #21212 on Mymetics Corp (MYMX)

[bow-tie]

This study at HZI will evaluate the safety and immunogenicity of different virosome-based Covid-19 vaccine candidates by intramuscular and intranasal administrations. The virosome formulations will incorporate and evaluate two different SARS-CoV-2 antigens, one full length stabilized S protein, for which Mymetics is collaborating with the group of Dr. Rogier Sanders at the Amsterdam Medical Center of the University of Amsterdam, the Netherlands, and the second is a receptor binding domain recombinant protein of SARS-CoV-2.
https://apnews.com/press-release/accesswire/business-virus-outbreak-public-health-netherlands-severe-acute-respiratory-syndrome-4fa3df56061540968f3cf5e856154eb4

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
November 2020
DOI: 10.1101/2020.11.07.365726

Rogier Sanders
37.19Academisch Medisch Centrum Universiteit van Amsterdam

Recently, nasal immunization has been shown to dramatically improve SARS-CoV-2 vaccine efficacy over intramuscular dosing (Hassan et al., 2020). Using this alternative administration route may allow SARS-CoV-2 S-I53-50NPs to elicit protective NAb titers in the mucosa and could advance its protective efficacy towards fully sterilizing immunity.

https://www.researchgate.net/publication/345545496_Two-component_spike_nanoparticle_vaccine_protects_macaques_from_SARS-CoV-2_infection